COMMUNIQUÉS West-GlobeNewswire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
04/03/2019
COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced [...]
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
04/03/2019
Conference Call to be Held at 8:00am Eastern Time HOPKINTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel [...]
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
04/03/2019
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve [...]
Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
04/03/2019
WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Les résultats décisifs de l'essai clinique de Phase 2 de Bermekimab dans le traitement de la dermatite atopique (AD) seront présentés le 2 mars 2019 au Congrès annuel de l'American Academy of Dermatology
04/03/2019
Réduction moyenne rapide et significative des lésions cutanées, réduction moyenne de 66 % (p < 0,001) et 76 % (p < 0,001) du score EASI, respectivement en 4 et 7 semaines. Résolution rapide et significative des [...]
Huddle handoff communication tool improves process of addressing workplace violence in health care
04/03/2019
Study appears in February 2019 issue of The Joint Commission Journal on Quality and Patient Safety OAKBROOK TERRACE, Ill., March 04, 2019 (GLOBE NEWSWIRE) -- Health care workplace violence is increasing in the United [...]
UPDATE -- Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis
04/03/2019
VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal [...]
ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference
04/03/2019
– Investor Webinar Now Available on Company's Website – EDISON, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and [...]
Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis
04/03/2019
VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal [...]
Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
04/03/2019
Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank Proceeds strengthen balance sheet and cash visibility Payment triggered by the achievement of 2 key [...]
Nanobiotix reçoit un versement de 14 millions d’euros au titre de la deuxième tranche du prêt accordé par la Banque Européenne d’Investissement
04/03/2019
Nanobiotix reçoit un versement de 14 millions d’euros au titre de la deuxième tranche du prêt accordé par la Banque Européenne d’Investissement Renforcement du bilan et de la visibilité financière Versement déclenché [...]
Gradalis Announces Medical Leadership Team Promotion
04/03/2019
DALLAS, March 04, 2019 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications, today announced the [...]
Medexus Pharmaceuticals annonce une augmentation de 512% de son chiffre d’affaires, qui passe à 14,4 millions de dollars pour le troisième trimestre de l’exercice 2019
04/03/2019
La société génère un BAIIA ajusté de 2,2 millions de dollars MONTRÉAL, 04 mars 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « Société » ou « Medexus ») (TSXV : MDP, OTCQB : [...]
Segra Deploys Disruptive Cannabis DNA Sequencing Platform
04/03/2019
VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Segra International Corp. (“ Segra ” or the “ Company ”), a cannabis agritech company, is pleased to announce that its Genotyping and Molecular Lab [...]
EssilorLuxottica :Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2019
04/03/2019
Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2019 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 28 février 2019
04/03/2019
Nombre total de droits de vote et d'actions composant le capital social au 28 février 2019 (Conformément à l'article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l'AMF) [...]
VALNEVA : Déclaration d'actions et de droits de vote - FEVRIER 2019
04/03/2019
VALNEVA Déclaration d'actions et de droits de vote - FEVRIER 2019 Dénomination sociale : VALNEVA Adresse du siège social : 6 rue Alain Bombard, 44800 Saint-Herblain Marché réglementé Euronext Paris de Nyse Euronext - [...]
Nicox: Number of voting rights as of February 28. 2019
04/03/2019
Nicox SA Société anonyme with a registered capital of € 29,909,120 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On March 4, 2019, MONTHLY PUBLICATION OF THE [...]
Nicox : Nombre de droits de vote au 28 février 2019
04/03/2019
Nicox SA Société anonyme au capital de 29 909 120 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 4 mars 2019, PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS [...]

Pages